This is a preview of subscription content, log in via an institution to check access.
Reference
Claudiani S, et al. Dose reduction of first and second generation tkis is effective in the maintenance of major molecular response and may predict successful TFR in CML patients. Blood 132 (Suppl. 1): Nov 2018. Available from: URL: http://www.bloodjournal.org/page/ash-annual-meeting-abstracts [abstract] - United Kingdom
Rights and permissions
About this article
Cite this article
Nilotinib. Reactions Weekly 1746, 143 (2019). https://doi.org/10.1007/s40278-019-59580-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-59580-1